Skip to main content

Dr. Paul D. Rosenblit, M.D.

Endocrinology & Diabetes (Endocrinology, Diabetes & Metabolism Physician)

  • Medicare participating

At a glance

Years since graduation
45
In the NPI registry since
2006
Medicare patients seen, 2024
433

Licensed in California since 1982, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Endocrinology, Diabetes & Metabolism Physician primary
    CA license A39224 (first issued 1982; current)
  • Specialist
    CA license A039224

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Endocrinology & Diabetes per capita by county →

Where they work

Hospitals

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
433
Services billed
890
Patients’ average age
76
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 30-39 minutes870454
New patient office or other outpatient visit, 60-74 minutes5555
Established patient office or other outpatient visit, 40-54 minutes2019
Established patient office or other outpatient visit, 20-29 minutes1616

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 24 companies reported 59 payments worth $8,986 in total to this clinician.

By company
Ionis Pharmaceuticals, Inc.$6,926
Novo Nordisk Inc$286
Amgen Inc.$278
Bayer HealthCare Pharmaceuticals Inc.$259
Ascendis Pharma Endocrinology Inc$201
Corcept Therapeutics$159
Recordati_rare_diseases_inc.$132
Kyowa Kirin, Inc.$122
By type
Consulting Fee$6,751
Food and Beverage$2,130
Travel and Lodging$63.00
Education$42.50

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Dec 13, 2025Ionis Pharmaceuticals, Inc.
Dec 13, 2025
Consulting Fee
OLEZARSEN · CARDIOLOGY
$6,751
Dec 13, 2025Ionis Pharmaceuticals, Inc.
Dec 13, 2025
Travel and Lodging
OLEZARSEN · CARDIOLOGY · travel to CARLSBAD, CA · in-kind
$63.00
Mar 29, 2025Mannkind Corporation
Mar 29, 2025
Education
AFREZZA · DIABETES MEDICINE · in-kind
$42.50

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in California →

Industry-funded research

Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $44,826 in research payments for these studies, mostly to the institutions running them.

  • Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT)
    Novartis Pharmaceuticals Corporation
  • Study name not reported
    Novo Nordisk As
  • Study name not reported
    Ionis Pharmaceuticals, Inc.
  • A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease
    Novartis Pharmaceuticals Corporation

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Endocrinology & Diabetes clinicians in Huntington Beach

Sources

NPI registry (CMS NPPES, November 2026; record last updated August 20, 2019), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1699862102. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.